{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+FTC%2FTAF", "query": { "intervention": "Placebo to FTC/TAF" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+FTC%2FTAF&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T15:49:31.498Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04493216", "title": "A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "FTC/TAF", "type": "DRUG" }, { "name": "Dolutegravir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2020-11-18", "completion_date": "2023-05-29", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-09-22T15:49:31.498Z", "location_count": 9, "location_summary": "Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Berkley", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493216" }, { "nct_id": "NCT03110380", "title": "Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" }, { "name": "DTG Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" }, { "name": "B/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 567, "start_date": "2017-06-12", "completion_date": "2021-02-10", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-09-22T15:49:31.498Z", "location_count": 66, "location_summary": "Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03110380" }, { "nct_id": "NCT02607956", "title": "Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "DTG", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "DTG Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" }, { "name": "B/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 657, "start_date": "2015-11-11", "completion_date": "2021-07-05", "has_results": true, "last_update_posted_date": "2022-03-07", "last_synced_at": "2026-09-22T15:49:31.498Z", "location_count": 74, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 53 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607956" }, { "nct_id": "NCT03547908", "title": "Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1/HBV Co-Infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" }, { "name": "Placebo to match DTG", "type": "DRUG" }, { "name": "Placebo to match F/TDF", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" }, { "name": "F/TDF", "type": "DRUG" }, { "name": "Placebo to match B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2018-05-30", "completion_date": "2024-03-07", "has_results": true, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-09-22T15:49:31.498Z", "location_count": 4, "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Berkley", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03547908" }, { "nct_id": "NCT06333808", "title": "Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Bictegravir", "type": "DRUG" }, { "name": "Lenacapavir", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "Placebo to match B/F/TAF", "type": "DRUG" }, { "name": "Placebo to match BIC/LEN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 577, "start_date": "2024-03-25", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-22T15:49:31.498Z", "location_count": 51, "location_summary": "Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06333808" }, { "nct_id": "NCT01797445", "title": "Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "E/C/F/TDF Placebo", "type": "DRUG" }, { "name": "E/C/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 872, "start_date": "2013-03-12", "completion_date": "2018-10-03", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-09-22T15:49:31.498Z", "location_count": 79, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01797445" }, { "nct_id": "NCT04006704", "title": "Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "D/C/F/TAF FDC placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Pharmaceutica N.V., Belgium", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 25, "start_date": "2019-10-10", "completion_date": "2020-03-06", "has_results": false, "last_update_posted_date": "2021-07-06", "last_synced_at": "2026-09-22T15:49:31.498Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04006704" }, { "nct_id": "NCT04600687", "title": "B/F/TAF Ease of Swallowability Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Placebo tablets", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2018-11-06", "completion_date": "2020-10-10", "has_results": false, "last_update_posted_date": "2020-10-23", "last_synced_at": "2026-09-22T15:49:31.498Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04600687" }, { "nct_id": "NCT02607930", "title": "Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "ABC/DTG/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "ABC/DTG/3TC Placebo", "type": "DRUG" }, { "name": "B/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 631, "start_date": "2015-11-13", "completion_date": "2021-07-02", "has_results": true, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-09-22T15:49:31.498Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607930" }, { "nct_id": "NCT06630286", "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "ISL/LEN", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "PTM B/F/TAF", "type": "DRUG" }, { "name": "PTM ISL/LEN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 609, "start_date": "2024-10-09", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-09-22T15:49:31.498Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630286" } ] }